Article
Therapy-Induced Clonal Selection as a Driver of Response to JAK Inhibitors in Myelofibrosis
2026-06-23
Abstract excerpt
Myelofibrosis (MF) originates from the stepwise acquisition of somatic mutations in Hematopoietic Stem and Progenitor Cells (HSPCs). Alongside driver events triggering JAK-STAT pathway hyperactivation, several additional mutations, usually affecting the epigenetic machinery, contribute defining therapeutic response. Specifically, JAK-inhibition (JAKi) relieves MF symptoms but rarely eradicates the neoplastic clon...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 690f8406-5a14-5e1a-9ed4-10e3829c1048
- DOI
- 10.64898/2026.06.20.733514
